Structure base drug discovery company
Amura Holdings Ltd., Minerva Building, Babraham Research Campus, Babraham, CB22 3AT, U.K.
Board of Directors
Senior Management
Company Information

Licensing Opportunities

Licensing and partnering opportunities are available for Amura’s drug discovery programmes, technologies and intellectual property portfolio.  Amura adopts a flexible approach to licensing and partnering opportunities and welcomes enquiries from interested parties.

Licensing and partnering opportunities are available for:

 AMcore (Factsheet  )
AMcore™ provides a turnkey solution for the discovery of fully reversible ‘fast-on, slow-off ’ inhibitors of cathepsin proteases, a family of enzymes associated with numerous commercially attractive therapeutic areas.  AMcore™ was conceived, designed, developed and patented by Amura scientists, providing a very strong IP position that has matured to grant in major territories.

The potential of our candidates is highlighed through  oral-dosed proof-of-concept ("PoC")  studies in models of chronic neuropathic pain and rheumatoid arthritis with inhibitors of Cathepsin S; models of osteoprosis, osteoarthritis, rheumatoid arthritis and bone metastasis with inhibitors of Cathepsin K; models of arthritic diseases with inhibitors of a mixed S/K profile. The data is excellent and confirms the potential of these molecules as clinical candidate drugs. In addition to the PoC efficacy data, the quality of the molecules is confirmed by a comprehensive pre-clinical package which includes pharmacokinetic data, selectivity and safety assessment.  For each indication, the development candidate and a first rate back-up molecule are now available for partnering.  

Amura is seeking partners with a common vision towards progression and commercialisation of these first in class therapeutics.

Full Compound Information Summaries are available from Amura under a Confidentiality Agreement. 

 ß-lactamase inhibitors  (Factsheet )
The ß-lactamase inhibitors (BLIs) are positioned as combination partner compounds for ß-lactam antibiotics including: penicillins, cephalosporins and carbapenems to be used in first-line i.v. treatments for broad-spectrum hospital-acquired bacterial infections.  Amura is seeking partners with a common vision towards progression and commercialisation of these combination therapeutics.

Contact details:

Dr. Dan Roach
Tel: +44(0)1954 211515
Click here

Dr. David Brown
Tel: +44(0)1954 211515
Click here


Phone: +44(0)1223 839797 Fax: +44(0)1223 839898 Copyright © 2009 Amura Holdings Ltd.